Stratec Biomedical AG (ETR:SBS) has earned a consensus rating of “Hold” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is €60.50 ($72.02).
Several brokerages recently issued reports on SBS. Oddo Bhf set a €58.00 ($69.05) price target on Stratec Biomedical and gave the company a “neutral” rating in a research note on Monday, October 23rd. Berenberg Bank set a €59.00 ($70.24) price target on Stratec Biomedical and gave the company a “neutral” rating in a research note on Thursday, December 7th. Warburg Research set a €62.00 ($73.81) price target on Stratec Biomedical and gave the company a “buy” rating in a research note on Thursday, October 26th. Kepler Capital Markets set a €70.00 ($83.33) price target on Stratec Biomedical and gave the company a “buy” rating in a research note on Friday, October 27th. Finally, Deutsche Bank set a €56.00 ($66.67) price objective on Stratec Biomedical and gave the company a “neutral” rating in a research note on Tuesday, October 24th.
Shares of Stratec Biomedical (ETR SBS) opened at €67.40 ($80.24) on Friday. Stratec Biomedical has a 52 week low of €44.52 ($53.00) and a 52 week high of €70.33 ($83.73). The firm has a market capitalization of $803.47 and a P/E ratio of 29.43.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/06/stratec-biomedical-ag-sbs-receives-average-recommendation-of-hold-from-analysts.html.
Stratec Biomedical Company Profile
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.
Receive News & Ratings for Stratec Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.